

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

**STA Cabozantinib for treating advanced neuroendocrine
tumours that have progressed after systemic treatment
[ID6474]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?
No

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?
Yes, it was highlighted that people from Black ethnic backgrounds have a higher incidence of neuroendocrine tumours (NETs) and can have poorer outcomes. Stakeholders noted that people may experience inequalities linked to age, disability, mobility, financial circumstances, or geographical distance from specialist NET centres. They also stated that differences can arise from language and culture, which may limit understanding of treatment and side-effect management. The committee noted that issues relating to differences in the prevalence or incidence of a condition, or access to care, are not issues that can be addressed by a NICE technology appraisal recommendation.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No other potential equality issues were identified by the committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

Yes, section 3.20 of the draft guidance.

Approved by Associate Director (name): Ross Dent

Date: 22/09/2025

Final draft guidance

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

No other issues raised.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No

5. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?

Yes, section 3.19 – Equality in the final draft guidance

Approved by Associate Director (name): Ross Dent

Date: 01/04/2026